What You Should Know:
- Pepticom, an innovator in AI-driven peptide-based therapeutics secures $6.6M in a Series A1 funding round led by Japan Israel High Tech Ventures 2 LP, with strong support from existing investors.
- The new funding will accelerate the development of Pepticom's oral IL-17 inhibitor program, focusing on creating improved treatments for autoimmune diseases like psoriasis and psoriatic arthritis.
Revolutionizing Autoimmune Disease Treatment
Pepticom is
Read More
Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant
M&A: Predictive Oncology to be Acquired by Renovaro
What You Should Know:
- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced its upcoming acquisition by Renovaro, Inc. (NASDAQ: RENB) in a strategic move aimed at accelerating innovation and improving cancer treatment outcomes.
- The merger brings together two companies with a shared commitment to leveraging artificial intelligence and machine learning to transform cancer care.
Synergistic Strengths and Shared Vision
Both Predictive
Read More
BrightInsight, Sanofi to Build Drug Companion Apps for its Major Specialty Therapies
What You Should Know:
- BrightInsight, Inc., a provider of regulated digital health solutions, has announced an expanded multi-year partnership with Sanofi, a global biopharmaceutical company. This expanded partnership builds on a successful collaboration that began in 2022 when Sanofi selected the BrightInsight Platform to accelerate the development of a SaMD for one of its specialty care medicines.
- The goal of the collaboration aims to accelerate Sanofi's drug development timeline and
Read More
GeneDx Launches Tool to Fuel Rare Disease Drug Discovery
What You Should Know:
- GeneDx, a leader in genomic insights, has announced the launch of GeneDx Discover, a groundbreaking data visualization tool designed to revolutionize drug discovery and development.
- The platform provides biopharmaceutical companies with access to de-identified and aggregated genetic data, empowering them to accelerate the development of new therapies.
Addressing the Challenges of Drug Development
The traditional drug development process is
Read More
NVIDIA BioNeMo Framework Accelerates AI Drug Discovery
What You Should Know:
- NVIDIA announced widespread adoption of its open-source BioNeMo™ Framework by pharmaceutical companies, techbio innovators, and AI researchers to accelerate drug discovery and molecule design.
- The framework provides a powerful suite of tools for scaling AI models in biomolecular research, bringing supercomputing capabilities to the forefront of drug development.
Accelerating Drug Discovery with AI
The BioNeMo Framework addresses the growing need
Read More
NVentures Invests in Genesis Therapeutics’ AI Platform for Drug Development
What You Should Know:
- Genesis Therapeutics, a company pioneering artificial intelligence (AI) technologies to create breakthrough medicines for patients, announced today a further equity investment from NVentures, NVIDIA’s venture capital arm.
- This investment is in addition to NVentures’ participation in the company’s $200 million Series B financing in August 2023.
Genesis Therapeutics Partners with NVIDIA to Advance AI-Driven Drug Discovery
Genesis Therapeutics, an AI-focused
Read More
Accenture Invests in 1910 Genetics to Accelerate AI-Powered Drug Discovery
What You Should Know:
- Accenture has made a strategic investment, through Accenture Ventures, in 1910 Genetics, a biotechnology company revolutionizing drug discovery with its AI-powered platform. Terms of the investment were not disclosed.
- The strategic collaboration will combine Accenture's expertise in scaling AI solutions with 1910 Genetics' innovative technology to help biopharmaceutical companies accelerate drug development, reduce costs, and deliver more effective therapies
Read More
Gilead Sciences and Genesis Therapeutics Partner on AI-Driven Drug Discovery
What You Should Know:
- Gilead Sciences, a global biopharmaceutical company, and Genesis Therapeutics, an AI-focused biotechnology firm, have announced a strategic collaboration to discover and develop innovative small molecule therapies.
- The startegic partnership leverages Genesis' cutting-edge AI platform, GEMS, to accelerate drug discovery and development.
A Powerful Collaboration
Genesis Therapeutics' GEMS platform utilizes advanced AI techniques to generate and
Read More
The Role of AI in Streamlining Drug Discovery and Clinical Trials: A New Era in Pharmaceutical Innovation
In the rapidly evolving world of pharmaceuticals, artificial intelligence (AI) is emerging as a game-changer. From accelerating drug discovery to enhancing the efficiency of clinical trials, AI is revolutionizing how new medicines are brought to market. This transformation is not just limited to the research and development phases; AI is also playing a critical role in ensuring that drugs meet regulatory standards.
The AI Revolution in Drug Discovery
Drug discovery has traditionally been a
Read More
Quantiphi Invests in Transcell to Advance AI-Driven Drug Discovery
What You Should Know:
- Quantiphi, an AI-first digital engineering company, announced a strategic minority investment in Transcell, a pioneering stem cell-based biotech innovator. This collaboration marks a significant step forward in the integration of AI and biotechnology for drug discovery and development.
- By combining Quantiphi’s AI expertise with Transcell’s stem cell technology, the partnership aims to accelerate the development of innovative treatments while reducing
Read More
